Stockholm-based Karolinska Development AB said that top-line data from portfolio company Modus Therapeutics AB's phase II study of sevuparin did not show a meaningful benefit in the management of acute vaso-occlusive crisis (VOC) in patients with sickle cell disease (SCD), sending company shares (Nasdaq Stockholm:KDEV) down 9.9% to SEK3.90 (US41 cents) Monday. Modus is now considering its options for further development of sevuparin in other indications where its multimodal action may have utility, said Viktor Drvota, CEO of Karolinska Development.